Shanghai Juncell Therapeutics Co., Ltd.

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics) is a Chinese clinical-stage biotechnology company founded in 2019 and headquartered in Shanghai. It focuses on the research, development and commercialization of innovative cell therapies for solid tumors, with a pipeline built around tumor-infiltrating lymphocyte (TIL) technology. The company describes itself as developing first-in-class or best-in-class autologous natural TIL and gene-modified TIL products covering multiple disease stages and treatment settings, from early adjuvant therapy to late-line treatment. Juncell's technology foundation rests on three proprietary platforms: DeepTIL™, a TIL cell expansion platform; NovaGMP™, a gene-modification platform; and RiverTIL™, an endogenous TIL platform. According to the company, DeepTIL™ can obtain clinical-grade TIL cells from different types of tumor tissue with a high culture success rate, without relying on healthy-donor PBMC as feeder cells, and without the need for high-intensity lymphodepleting chemotherapy or IL-2 administration. NovaGMP™ is a non-viral vector gene-modification system intended to avoid replication-competent virus risk and reduce modification cost, with reported average modification efficiency above 45% and post-modification TIL viability above 90%. RiverTIL™ is designed to pre-manufacture and cryopreserve TIL seed cells from previously resected tumor tissue so that TIL cells can self-amplify inside the patient's body, potentially shifting TIL therapy from a highly personalized model toward a "quasi-off-the-shelf" paradigm. The lead pipeline includes GC101, described as the world's first natural TIL cell drug that requires neither high-intensity lymphodepleting chemotherapy nor IL-2 administration, and which the company hopes will become China's first approved TIL therapy. GC101 has been studied in patients with melanoma and non-small cell lung cancer who failed multiple lines of treatment, and its registrational Phase II data were selected as a late-breaking abstract for the ASCO 2026 annual meeting. GC203 is described as the world's first non-viral vector gene-modified TIL therapy; it received implied clinical trial approval from China's National Medical Products Administration (NMPA) for refractory solid tumors including ovarian cancer and pancreatic cancer, and has shown efficacy and safety in late-line advanced ovarian cancer. Juncell has built a TIL cell industrialization base of more than 16,000 square meters and a research headquarters including a 2,000-square-meter GMP workshop and quality-control laboratory. The company participated as a drafting unit in China's first TIL group standard and, in February 2026, obtained China's first drug manufacturing license for the TIL therapy category. It has completed multiple financing rounds totaling nearly RMB 800 million, backed by investors including Cathay Capital (凯泰资本), Oriza Seed (元禾原点), FuRong Investment (复容投资), YuanBio Venture Capital (元生创投) and Huangpu Medical Fund (黄埔医药基金). The founder, CEO and CTO is Dr. Jin Huajun (金华君), a State Council special allowance expert with more than 20 years of cross-disciplinary academic, clinical and industry experience.

Shanghai Juncell Therapeutics Co., Ltd. was founded in 2019 in Shanghai as a biotechnology company dedicated to innovative cell therapies for solid tumors. Its early years were focused on building research infrastructure and preclinical capabilities. In 2020 the company completed construction of its R&D laboratory and offices, completed preclinical research on TIL therapies, and closed a Pre-A financing round. In 2021 Juncell launched an investigator-initiated trial (IIT) for GC101 and completed Series A and A+ financing. The following year, 2022, was a period of rapid pipeline advancement: the company completed preclinical research on GC203, obtained IND approval for GC101 clinical trials, started a Phase I trial of GC101, initiated an IIT for GC203, and completed an A++ financing round. Progress continued in 2024 with IND approval for GC203, the start of its Phase I trial, the launch of a Phase II trial of GC101 in melanoma, the start of an Ib/II trial of GC101 in non-small cell lung cancer, the opening of the TIL cell industrialization base, and completion of a Series B financing round. In 2025 the first patient was enrolled in the GC101 melanoma Phase II trial; the company obtained IND approval for a Phase II trial of GC101 combined with a PD-1 antibody in advanced malignant solid tumors; it reached its patient enrollment target for the GC101 melanoma Phase II trial; and it completed Series B+ and Series C financing rounds. By 2026 the company reported that GC101 registrational Phase II data were selected as a late-breaking abstract for the ASCO 2026 annual meeting, and that in February 2026 it obtained China's first drug manufacturing license for the TIL therapy category. Juncell has also participated as a drafting unit in China's first TIL group standard. Across multiple financing rounds, the company has raised nearly RMB 800 million from investors including Cathay Capital, Oriza Seed, FuRong Investment, YuanBio Venture Capital and Huangpu Medical Fund. Its founder, CEO and CTO is Dr. Jin Huajun, who has more than 20 years of cross-disciplinary experience spanning academia, hospitals and industry.

• 2026

  GC101 registrational Phase II data selected as ASCO 2026 late-breaking abstract; obtained China's first drug manufacturing license for TIL therapy category in February 2026

• 2025

  First patient enrolled in GC101 melanoma Phase II trial; obtained IND approval for GC101 plus PD-1 antibody Phase II trial; reached enrollment target for GC101 melanoma Phase II trial; completed Series B+ and Series C financing

• 2024

  Obtained GC203 IND approval; started GC203 Phase I trial; launched GC101 Phase II melanoma trial; started GC101 NSCLC Ib/II trial; TIL industrialization base began operations; completed Series B financing

• 2022

  Completed GC203 preclinical research; obtained GC101 IND approval; started GC101 Phase I trial; launched GC203 IIT; completed A++ financing

• 2021

  Launched GC101 IIT study; completed Series A and A+ financing

• 2020

  Completed R&D laboratory and office construction; completed preclinical research on TIL; completed Pre-A financing

• 2019

  Company founded

Clinical-stage biotech developing first-in-class/best-in-class, more accessible and affordable TIL cell therapies for solid tumors.

• GC101

  Natural TIL cell therapy described as the world's first requiring no high-intensity lymphodepleting chemotherapy and no IL-2 administration; studied in advanced melanoma and NSCLC; registrational Phase II data selected as ASCO 2026 late-breaking abstract.

• GC203

  Gene-modified TIL therapy described as the world's first non-viral vector gene-modified TIL therapy; received NMPA implied clinical trial approval for refractory solid tumors including ovarian and pancreatic cancer.

• DeepTIL™

  TIL cell expansion platform enabling clinical-grade TIL cells from different tumor tissues with high success rate, without healthy-donor PBMC feeder cells and without high-intensity lymphodepletion or IL-2.

• NovaGMP™

  Non-viral vector gene modification platform with no replication-competent virus risk, significantly lower cost than viral vectors, average modification efficiency >45% and post-modification TIL viability >90%.

• RiverTIL™

  Endogenous TIL expansion platform that pre-manufactures and cryopreserves TIL seed cells from previously resected tumor tissue for self-amplification in the patient's body, aiming to reduce cost and production time.

1. 1上海君赛生物股份有限公司官网首页juncell.com
2. 2关于君赛-上海君赛生物股份有限公司juncell.com
3. 3产品管线-上海君赛生物股份有限公司juncell.com
4. 4Wikidata: Shanghai Juncell Therapeutics Co., Ltd. (China)wikidata.org
5. 5关于君赛-上海君赛生物股份有限公司juncell.com